Berzosertib

Synonyms: VE-822; VX-970; M6620
Berzosertib (VE-822) 是一种具有口服活性、可穿透血脑屏障的选择性 ATR 激酶抑制剂,可通过阻断 ATR 激酶活性、消除 G2/M 细胞周期检查点并损伤 DNA 损伤修复功能,诱导细胞凋亡 (apoptosis),抑制克隆迁移与细胞增殖,并激活癌细胞中的 cGAS-STING 轴,可用于头颈部鳞状细胞癌、结直肠癌等癌症相关研究。
产品编号: MS-M08885 纯度: 99.44% CAS No.: 1232416-25-9 分子式: C24H25N5O3S 分子量: 463.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价
1g
询价
询价
5g
询价
询价
10g
询价
询价

产品描述

Berzosertib (VE-822) 是一种具有口服活性、可穿透血脑屏障的选择性 ATR 激酶抑制剂,可通过阻断 ATR 激酶活性、消除 G2/M 细胞周期检查点并损伤 DNA 损伤修复功能,诱导细胞凋亡 (apoptosis),抑制克隆迁移与细胞增殖,并激活癌细胞中的 cGAS-STING 轴,可用于头颈部鳞状细胞癌、结直肠癌等癌症相关研究。

生物实验数据

生物活性 Berzosertib (VE-822) is an orally active, blood-brain barrier-penetrant, selective ATR kinase inhibitor that blocks ATR kinase activity, abolishes the G2/M cell cycle checkpoint, and impairs DNA damage repair, thereby inducing apoptosis, inhibiting clonogenic migration and cell proliferation, and activating the cGAS-STING axis in cancer cells, and it can be used for cancer-related research such as head and neck squamous cell carcinoma and colorectal cancer.
IC50 & Target ATR:19 nM, PI3Kγ:220 nM (Ki), ATM:34 nM (Ki)
体外研究
(In Vitro)

Berzosertib (0.031-1 µM; 72 h) 可降低 Cal-27 和 FaDu 头颈部鳞状细胞癌 (HNSCC) 细胞系的细胞活力,其 IC50 值分别为 0.285 µM 和 0.252 µM。
Berzosertib (0.125-0.5 µM; 24-48 h) 可抑制 Cal-27 和 FaDu 头颈部鳞状细胞癌 (HNSCC) 细胞的迁移。
Berzosertib (0.25-0.5 µM; 48 h) 可诱导 Cal-27 和 FaDu 细胞发生凋亡。
Berzosertib (48-72 h) 可抑制 A549、NCI-H226 和 NCI-H520 细胞的增殖,其 IC50 值处于 1-4 μM 范围。
Berzosertib (40-80 nM; 1 h) 可增强 A549、NCI-H226 和 NCI-H520 非小细胞肺癌 (NSCLC) 细胞系的放射敏感性。
Berzosertib (40 nM; 1 h) 可抑制 A549、NCI-H226 和 NCI-H520 非小细胞肺癌 (NSCLC) 细胞系中辐射诱导的 ATR (Thr1989) 磷酸化,且不影响 ATM (Ser1981) 的激活。
Berzosertib (40 nM; 1 h) 可消除 A549 非小细胞肺癌细胞中辐射诱导的 G2/M 细胞周期检查点,使细胞进入 G1 期。
Berzosertib (40-80 nM; 1 h) 与 10 Gy 而非 2 Gy 的辐照联合使用时,可增强 A549 非小细胞肺癌细胞中辐射诱导的细胞凋亡。
Berzosertib (40 nM; 1 h) 可抑制 A549 细胞中的 DNA 双链断裂修复。
Berzosertib (1 µM; 2 h) 可破坏 HCT116 和 CT26 细胞中辐射诱导的 G2/M 检查点的启动与维持,促进 DNA 损伤后的有丝分裂进入。
Berzosertib (1 µM; 2 h) 联合 5 Gy 辐照可提高 HCT116 和 CT26 结直肠癌细胞系中的微核形成水平与胞质双链 DNA 含量。
Berzosertib (1 µM; 2 h) 联合 5 Gy 照射可强效激活经典 cGAS-STING-pTBK1/pIRF3 通路,并在 HCT116、SW480、CT26 和 MC38 细胞中上调干扰素刺激基因 CXCL10、CCL5 和 IFNB 的表达。
Berzosertib (1 µM; 2 h) 联合 5 Gy 辐照可抑制 SHP1 向 HCT116 细胞中 TRAF6/STING 复合物的募集,增强 TRAF6 与 STING 的相互作用。

Cell Proliferation Assay

Cell Line: Cal-27, FaDu cells
Concentration: 0.125; 0.25; 0.5 µM
Incubation Time: 24 h (Cal-27); 48 h (FaDu)
Result: Reduced Cal-27 cell gap closure to 82% at 0.25 µM and 50% at 0.5 µM at 24 h, compared to 98% in untreated cells.
Reduced FaDu cell gap closure to 24% at 0.25 µM and 0.5 µM at 24 h, compared to 41% in untreated cells.
Significantly inhibited FaDu cell gap closure at 0.5 µM at 48 h.

Cell Viability Assay

Cell Line: Cal-27, FaDu cells
Concentration: 0.031; 0.063; 0.125; 0.25; 0.5; 1 µM
Incubation Time: 72 h
Result: Caused a dose-dependent decrease in cell viability in both cell lines.
Exhibited an IC50 value of 0.285 µM for Cal-27 cells.
Exhibited an IC50 value of 0.252 µM for FaDu cells.

Apoptosis Analysis

Cell Line: Cal-27, FaDu cells
Concentration: 0.25 µM (Cal-27); 0.5 µM (FaDu)
Incubation Time: 48 h
Result: Increased apoptosis levels to 279% of control in Cal-27 cells.
Increased apoptosis levels to 244% of control in FaDu cells.

Western Blot Analysis

Cell Line: A549, NCI-H226, and NCI-H520 cells
Concentration: 40 nM
Incubation Time: 1 h
Result: Did not affect radiation-induced ATM (Ser1981) phosphorylation.
Diminished radiation-induced activation of p-ATR (Thr1989) in all three cell lines even at 24 h post-radiation.

Apoptosis Analysis

Cell Line: A549 cells
Concentration: 40; 80 nM
Incubation Time: 1 h
Result: Showed no increase in apoptosis when combined with 2 Gy radiation.
Caused a significant increase in apoptosis when combined with 10 Gy radiation, compared to radiation alone.

Immunofluorescence

Cell Line: A549 cells
Concentration: 40 nM
Incubation Time: 1 h
Result: Combined with irradiation resulted in a statistically significant increase in the number of γH2AX foci at 8 h and 24 h compared with cells treated with irradiation alone.

Real Time qPCR

Cell Line: HCT116, SW480, CT26, MC38
Concentration: 1 µM
Incubation Time: 2 h
Result: Caused a sharp, time-dependent increase in mRNA levels of CXCL10, CCL5, and IFNB in HCT116 and CT26 cells, with peak expression at 8-12 hours post-irradiation.
Induced significant increases in CXCL10, CCL5, and IFNB gene expressions in SW480 and MC38 cells compared to irradiation alone.
体内研究
(In Vivo)

Berzosertib (60 mg/kg;口服;每日一次;连续 10 天;2 Gy 局部肿瘤照射前 1 小时) 与每日 2 Gy 局部照射协同作用,可延缓小鼠皮下非小细胞肺癌脑转移 PDX 模型的肿瘤生长。
Berzosertib (60 mg/kg;口服;每日 1 次;连续 5 天;于 2.5 Gy 全脑照射前 1 小时给药) 联合每日 2.5 Gy 全脑照射,可显著提升小鼠 NSCLC 脑转移异种移植模型的中位总生存期并抑制颅内肿瘤生长。
Berzosertib (60 mg/kg;灌胃;于 Gy 射线照射前 2 小时给药,随后每日给药 1 次,连续 3 天) 与 5 Gy 照射及抗 PD-L1 联合使用时,在小鼠 MC38 和 CT26 模型中产生抗肿瘤活性。

Animal Model: Female Hsd:athymic Nude-Foxn1 mice (6-8-week-old) subcutaneously implantated with UW-lung-16 and UW-lung-18
Dosage: 60 mg/kg
Administration: p.o.; daily; 10 days; 1 h before 2 Gy local tumor irradiation
Result: Delayed growth of UW-lung-16 and UW-lung-18 tumors.
Reduced estimated tumor growth curve slope for UW-lung-16 tumors significantly lower than alone, with a synergistic effect and dose enhancement factor (DEF) of 1.8.
Reduced estimated tumor growth curve slope for UW-lung-18 tumors significantly lower than alone, with a synergistic effect and DEF of 1.4.
Inhibited phospho-Chk1 (Ser345) alone and combined with irradiation.
Increased cleaved caspase-3 in the combination group.
Induced significantly more γH2AX foci in the combination group compared to other groups.
Animal Model: Athymic nude mice intracranial implantation of luciferase-transfected UW-Lung-16 cells
Dosage: 60 mg/kg
Administration: p.o.; daily; 5 days; 1 h before 2.5 Gy whole brain irradiation
Result: Reduced bioluminescence total flux significantly by days 32 and 40 post-implant compared to radiation alone.
Improved median overall survival to 95 days, compared to 67 days in the radiation alone group.
Showed no significant difference in body weight between groups during or 40 days post-treatment.
Animal Model: Balb/C mice (female, 5-6 weeks old) subcutaneously injected with CT26 cells
Dosage: 60 mg/kg
Administration: i.g.; 2 h before Gy IR, then daily for 3 days
Result: Delayed tumor growth more effectively than dual or monotherapy regimens.
Extended mouse survival compared to other treatment groups.
Increased CD3+ and CD8+ tumor-infiltrating lymphocyte counts.
Elevated levels of CD11c+ MHC-II+ dendritic cells and CD11c+ CD8+ tumor-infiltrating dendritic cells.
Increased CD86 maturation marker mean fluorescence intensity.
Activated the canonical cGAS-STING-pTBK1/pIRF3 axis.
Activated the non-canonical STING-p65 axis.
Upregulated mRNA expression of innate immune-related genes Cxcl10, Ccl5, and Ifnb.
Decreased SHP1 mRNA levels and SHP1 interaction with TRAF6/STING via promoting SHP1 SUMOylation at lysine 127.
Animal Model: C57/B6J mice (female, 5-6 weeks old) subcutaneously injected with MC38 cells
Dosage: 60 mg/kg
Administration: i.g.; 2 h before Gy IR, then daily for 3 days
Result: complete tumor regression in some mice.
Extended mouse survival compared to other treatment groups.
Reduced tumor burden (as measured by bioluminescence total flux).
Decreased Ki67-positive proliferating cells.
Increased TUNEL-positive apoptotic cells.
Increased CD3+ and CD8+ tumor-infiltrating lymphocyte counts.
Elevated levels of CD11c+ MHC-II+ dendritic cells and CD11c+ CD8+ tumor-infiltrating dendritic cells.
Increased CD86 maturation marker mean fluorescence intensity.
Activated the canonical cGAS-STING-pTBK1/pIRF3 axis.
Activated the non-canonical STING-p65 axis.
Upregulated mRNA expression of innate immune-related genes Cxcl10, Ccl5, and Ifnb.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 463.55
分子式 C24H25N5O3S
CAS No. 1232416-25-9
别名 VE-822; VX-970; M6620

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.31 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 16.67 mg/mL (35.96 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1573 mL10.7863 mL21.5726 mL53.9316 mL
5 mM0.4315 mL2.1573 mL4.3145 mL10.7863 mL
10 mM0.2157 mL1.0786 mL2.1573 mL5.3932 mL
15 mM0.1438 mL0.7191 mL1.4382 mL3.5954 mL
20 mM0.1079 mL0.5393 mL1.0786 mL2.6966 mL
25 mM0.0863 mL0.4315 mL0.8629 mL2.1573 mL
30 mM0.0719 mL0.3595 mL0.7191 mL1.7977 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础